AMD accounts for 1.7–3.3% of all blindness diagnosed in India.

Ranibizumab is an agent approved by the US Food and Drug Administration (FDA) and European Medicine Agency (EMEA) for the treatment of wet AMD.

Biosimilar ranibizumab, Razumab™, approved by the Drug Controller General of India (DCGI) in 2015, provides a cost-effective alternative, which is accessible to Indian patients.

This report presents the effectiveness of Razumab in patients with wet AMD treated in a real-world setting.

Razumab (biosimilar ranibizumab) demonstrated improvements in visual acuity and disease outcomes in patients with wet AMD without new safety issues.